Amrit Lamba discusses how the findings of VERIFY may influence how primary care practitioners will approach first-line treatment of people with type 2 diabetes (4:32).
Guidance in addressing the diagnosis and treatment of prediabetes, intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC
Analysis of the GOLD study suggests that at least three-quarters of people with type 1 diabetes using multiple daily injections benefit from continuous glucose monitoring.
Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.
The “classic” metabolic contributors to early-onset type 2 diabetes risk in European people explain little of the risk in Asian people, shows a comparison of Scottish and Asian Indian cohorts.
Researchers at the 55th EASD Annual Meeting in Barcelona, Spain, have presented primary data and subanalyses from a number of the PIONEER trials investigating the efficacy of oral semaglutide in people with type 2 diabetes.
Aiming for the lowest international targets in glycated hemoglobin levels may not protect against retinopathy and nephropathy in patients with type 1 diabetes, research suggests.
The addition of dapagliflozin to standard treatment may be beneficial for patients with established heart failure and reduced ejection fraction, indicate findings from the DAPA-HF trial.
Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.
Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.
Editorial Board member Lori Berard discusses how the ambulatory glucose profile is quietly revolutionizing the analysis of blood glucose and glycemic control for patients and practitioners.
